Literature DB >> 32306527

SB5 adalimumab biosimilar in the treatment of psoriasis and psoriatic arthritis.

Antonella Di Cesare1, Greta Tronconi1, Thais M Fastame1, Elia Rosi1, Leonardo Pescitelli1, Federica Ricceri1, Francesca Prignano1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32306527     DOI： 10.1111/dth.13435

Source DB:  PubMed          Journal:  Dermatol Ther        ISSN： 1396-0296            Impact factor:   2.851


× No keyword cloud information.
  3 in total

1.  Long-term data on the proposed adalimumab biosimilar BCD-057 in patients with moderate to severe psoriasis: A randomized controlled trial.

Authors:  Alexey V Samtsov; Andrey L Bakulev; Vladislav R Khairutdinov; Muza M Kokhan; Tat'yana V Korotaeva; Iskander K Minullin; Olga A Vylegzhanina; Valery V Dubenskiy; Bulat V Khalilov; Alkes A Khotko; Olga S Zykova; Irina V Chumachenko; Alexander M Lukyanov; Antonina V Artemeva; Polina P Pukhtinskaia
Journal:  PLoS One       Date:  2022-02-07       Impact factor: 3.240

Review 2.  An Update Review of Biosimilars of Adalimumab in Psoriasis - Bioequivalence and Interchangeability.

Authors:  Xin Zhou; Zhuo Chen; Xinling Bi
Journal:  Drug Des Devel Ther       Date:  2021-07-08       Impact factor: 4.162

3.  Switching from originator adalimumab to biosimilar SB5 in a rheumatology cohort: persistence on treatment, predictors of drug interruption and safety analysis.

Authors:  Cosimo Bruni; Stefano Gentileschi; Giovanni Pacini; Marco Bardelli; Lorenzo Tofani; Francesca Bartoli; Caterina Baldi; Laura Cometi; Ginevra Fiori; Francesca Nacci; Luca Cantarini; Serena Guiducci; Alberto Moggi-Pignone; Bruno Frediani; Marco Matucci-Cerinic
Journal:  Ther Adv Musculoskelet Dis       Date:  2021-07-23       Impact factor: 5.346
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.